Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027
Jade Biosciences is progressing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), with encouraging Phase 1 results showing a significant reduction in IgA levels and a good safety profile. The company aims for quarterly dosing to improve patient adherence compared to competitors. Key interim results from the Phase 2 JUNIPER trial are anticipated in 2027.
Jade Biosciences Company Profile & Introduction
This document is intended to be a company profile and introduction for Jade Biosciences. The content is currently empty, suggesting it will provide foundational information about the company.
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55
H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?
Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average analyst target. The company remains unprofitable, with a Price-to-Book ratio of 3.4x, which is considered overvalued compared to industry peers.
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?
Jade Biosciences (JBIO) recently reported a Q2 2026 net loss of $55.77 million and a basic loss per share of $0.76. Despite strong year-to-date and one-year shareholder returns of 63.91% and 216.64% respectively, the stock has pulled back 3.81% over 90 days and trades at $23.21, significantly below the average analyst target of $50.13. The company's price-to-book ratio of 3.4x is considered overvalued compared to industry peers, reflecting expectations for its drug pipeline rather than current financial performance, as it remains unprofitable with no reported revenue.
Jade Biosciences Is Maintained at Buy by BTIG
BTIG has reiterated its "Buy" rating for Jade Biosciences. This indicates continued confidence from the firm in the company's stock performance.
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research
BTIG Research has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $77.00 from $74.00, reiterating a "buy" rating with a potential upside of 254.35%. Despite this, the company reported a quarterly loss of $0.76 per share, missing consensus estimates, and analysts anticipate a full-year loss of $2.54 per share. Institutional investors have recently adjusted their holdings in JBIO, which is a clinical-stage biotechnology company focused on inflammatory skin diseases.
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside
Analysts have raised the average 12-month price target for Jade Biosciences, Inc. (JBIO) stock from $45.89 to $46.44, with individual forecasts ranging from $25 to $77 per share. This new target suggests a potential upside of approximately 111% from the Aug. 7 closing price. The consensus rating among 11 analysts remains a "Buy," with no "Holds" or "Sells."
Jade Biosciences Releases Q2 2026 Financial Results
Jade Biosciences, Inc. reported a Q2 2026 loss per share of $0.76 and a net loss of $55.8M, reflecting ongoing investment in its biotech development pipeline. The company showed an 11.6% improvement in its per-share loss compared to the prior year. Despite the losses, Wall Street analysts hold a positive outlook, with 8 buy ratings and 1 hold rating.
Wedbush raises Jade Biosciences price target on pipeline progress
Wedbush has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $47 from $45, maintaining an Outperform rating due to consistent pipeline progress. The firm highlighted positive data for JADE101 in IgAN patients and announced a new program, JADE301, targeting dermatomyositis, expected to enter clinical trials in Q4 2026. This positive outlook follows a significant stock increase and recent financial activities, including a successful public offering and new analyst coverage.
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth
Jade Biosciences, Inc. has filed its quarterly report for Q2 2026, revealing a net loss of $96.1 million for the first half of the year. The company's total assets stood at $472.1 million as of June 30, 2026. The financial results highlight increased research and development efforts and overall asset growth.
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen
Jade Biosciences reported Q2 EPS of $(0.76), missing the analyst estimate of $(0.64) by 18.75%. This result indicates a widening of operational deficits, with a 11.63% increase in losses compared to the prior year's $(0.86) per share loss. The company's financial performance highlights challenges in cost management or revenue generation, raising investor concerns about near-term profitability.
Jade Biosciences reports $55.8 million Q2 net loss
Jade Biosciences (JBIO) reported a Q2 2026 net loss of $55.8 million, an increase from $32.1 million a year prior. Despite the loss, the company holds $461.2 million in cash and expects its runway to extend into Q4 2028. The biotechnology firm provided updates on its clinical trials, including Phase 2 testing for JADE101, a Phase 1 trial for JADE201, and the introduction of JADE301, alongside a recent $172.5 million public offering.
Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3
Jade Biosciences reported a Q2 2026 net loss of $55.8 million, with $461.2 million in cash, cash equivalents, and investments, providing a financial runway into Q4 2028. The company highlighted positive interim Phase 1 results for JADE101, which is advancing to Phase 2/3 trials for IgA nephropathy, and progressed other clinical programs including JADE201 and JADE301. R&D expenses increased to $50.1 million, reflecting heightened clinical and CMC activities.
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences announced its second quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 in IgA nephropathy and the initiation of a Phase 2 trial. The company also reported progress in its pipeline with JADE201 for rheumatoid arthritis and JADE301 for dermatomyositis, anticipating further clinical trial initiations and data readouts in 2027. Jade Biosciences finished the quarter with $461.2 million in cash, cash equivalents, and investments, projected to fund operations into the fourth quarter of 2028.
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 for IgA nephropathy, with a Phase 2 trial underway and a Phase 3 trial expected to begin in early 2027. The company also initiated dosing for JADE201 in rheumatoid arthritis and unveiled JADE301 for dermatomyositis, with a Phase 1 trial planned for Q4 2026. Jade Biosciences reported $461 million in cash, cash equivalents, and investments as of June 30, 2026, projected to fund operations into Q4 2028.
Jade Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview
Jade Biosciences Inc (JBIO) is projected to report a loss of 64 cents per share. This information comes from a Reuters earnings preview available on TradingView, with further details behind a paywall requiring unlimited access to news sources.
Jade Biosciences (Nasdaq:JBIO) - Stock Analysis
Jade Biosciences (Nasdaq:JBIO) is a biotechnology company developing therapies for autoimmune diseases, primarily focusing on JADE101 for IgA nephropathy. The company has a market cap of US$1.3 billion but is currently unprofitable and its earnings are forecasted to decline. Recent news highlights include positive Phase 1 results for JADE101, its advancement into Phase 2, a $150 million equity offering, and new executive appointments.
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Jade Biosciences, Inc. (JBIO) is highlighted as a promising biotech opportunity in the $20 billion IgA nephropathy market, with UBS initiating coverage with a Buy rating and a $45 price target for its lead program, JADE101. The company announced positive interim Phase 1 study findings for JADE101, showing significant IgA level reductions and a favorable safety profile, with plans to advance to Phase 2 and Phase 3 trials. Despite this potential, the article suggests that certain AI stocks may offer greater upside and less risk.
If You Invested $1,000 in Aerovate Therapeutics, Inc. (AVTE)
This article analyzes the historical performance of a $1,000 investment in Aerovate Therapeutics, Inc. (AVTE), a clinical-stage biopharmaceutical company. It details the company's focus on developing drugs for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) with its lead candidate AV-101. The article also covers the recent strategic review and proposed merger with Jade Biosciences, Inc. following disappointing Phase 2b trial results for AV-101.
Aerovate Therapeutics Inc (AVTE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Aerovate Therapeutics Inc (AVTE), including its current stock price and market capitalization. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The analysis is presented by TradingKey, which emphasizes that investment decisions should be made with caution as the information is general and not financial advice.
Aerovate Therapeutics Inc (AVTE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Aerovate Therapeutics Inc's (AVTE) shareholder structure, detailing major shareholders by proportion and type. It also includes institutional shareholding trends over several quarters, highlighting changes in shares held and ownership percentages, and lists related ETFs that include AVTE.
Aerovate Therapeutics Inc (AVTE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Aerovate Therapeutics Inc (AVTE) stock information, focusing on its dividend and stock split history. It indicates that the company has not distributed dividends in the past five years and has no recorded stock split events. The article also provides current stock quotes and market capitalization for AVTE.
Aerovate Therapeutics Inc (AVTE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses Aerovate Therapeutics Inc (AVTE) revenue breakdown, but states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It indicates that the company's financial information in these specific categories is currently unavailable. The page gives general stock information like market cap but lacks the detailed revenue segmentation expected from the title.
Aerovate Therapeutics Inc (AVTE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aerovate Therapeutics Inc (AVTE), including its support and resistance levels, various technical indicators, and moving averages. According to the analysis, the overall signal for AVTE is a "Buy" based on moving averages, with a mix of buy and sell signals from individual indicators. The piece also includes FAQs explaining technical ratings and moving averages for better understanding.
Aerovate Therapeutics Inc (AVTE) Institutional Confidence
This article from TradingKey provides an overview of institutional confidence in Aerovate Therapeutics Inc (AVTE). It lists major institutional shareholders including Fidelity Management & Research Company LLC, Fairmount Funds Management LLC, and RA Capital Management, LP, along with their shareholdings and recent changes. The stock closed at 2.680 USD with a market cap of 77.68M.
Aerovate Therapeutics Inc (AVTE) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Aerovate Therapeutics Inc (AVTE), focusing on various financial metrics. It includes data points for volatility, maximum drawdown, return-to-drawdown ratio, skewness, and liquidity over different timeframes. However, most of the specific numerical values for these risk indicators are not provided in the current snapshot.
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies
Jade Biosciences successfully completed a public offering of 11.5 million shares at $15.00 per share, raising $172.5 million before expenses. The proceeds, including those from the full exercise of the underwriters' overallotment option, will be used to fund clinical trials, preclinical studies, and manufacturing for its autoimmune disease therapies, such as the lead candidate JADE101. The offering was managed by Jefferies, TD Cowen, UBS Investment Bank, and LifeSci Capital.
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jade Biosciences announced the closing of its public offering of 11,500,000 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of $172.5 million, with shares sold at $15.00 each. The company plans to use the net proceeds to fund clinical trials, preclinical studies, manufacturing, and other general corporate purposes.
Latham & Watkins Advises Jade Biosciences on Public Offering of Common Stock
Latham & Watkins LLP advised Jade Biosciences, Inc. on its public offering of 10,000,000 shares of common stock at US$15.00 per share, expecting to raise gross proceeds of US$150 million. The offering is anticipated to close on June 5, 2026, with underwriters having a 30-day option to purchase an additional 1,500,000 shares. A corporate team from Latham, led by partners Cheston Larson and Matt Bush, represented Jade Biosciences in the transaction.
Jade Biosciences, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Jade Biosciences, Inc., a clinical-stage biotechnology company, announced a proposed underwritten public offering of its common stock or pre-funded warrants. The company intends to use the net proceeds, along with existing funds, to finance clinical trials, preclinical studies, manufacturing, and other research and development activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers for the offering, which is subject to market conditions.
Jade Biosciences Initiates First-in-Human Phase 1 Trial of BAFF-R Antibody JADE201
Jade Biosciences has begun a first-in-human Phase 1 clinical trial for JADE201, an investigational anti-BAFF-R monoclonal antibody aimed at treating autoimmune diseases like rheumatoid arthritis. This antibody is engineered to deplete B cells through enhanced antibody effector function and BAFF signaling blockade, with features like afucosylation for increased antibody-dependent cellular cytotoxicity and half-life extension for less frequent dosing. Interim data from the trial, which assesses safety, tolerability, pharmacokinetics, and pharmacodynamics, are anticipated in 2027.
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Jade Biosciences announced that the first participant has been dosed in its Phase 2 JUNIPER trial, evaluating JADE101 for immunoglobulin A nephropathy (IgAN). JADE101 is designed to block APRIL, a key driver in IgAN, with interim data from the trial expected in 2027. The clinical-stage biotechnology company aims to develop best-in-class therapies for autoimmune diseases.
TradingKey
This page provides an overview of Aerovate Therapeutics Inc. (AVTE) stock information on TradingKey. It displays current stock price, market cap, and offers sections for financials, discussions, and analysis, indicating that the displayed content is a stock quote and company information page rather than a news article.
Attachment
Aerovate Therapeutics, Inc., a biopharmaceutical company specializing in rare cardiopulmonary diseases, has appointed Timothy Noyes as its new Chief Executive Officer. Noyes, a veteran in the biotechnology industry, was also elected to the company's Board of Directors in April 2021. This appointment signifies a leadership change aimed at advancing the company's drug development efforts.
Aerovate Therapeutics (NASDAQ:AVTE) Trading Up 14% - What's Next?
Aerovate Therapeutics (NASDAQ:AVTE) saw its stock jump 14% on Thursday, trading with significantly increased volume. This surge was accompanied by increased institutional buying from firms like Goldman Sachs, Jane Street, Rhumbline Advisers, and AQR Capital Management. The clinical-stage biopharmaceutical company focuses on inhaled therapies for pulmonary diseases, with its lead candidate targeting idiopathic pulmonary fibrosis (IPF) currently in early-phase trials.
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics
The Pulmonary Arterial Hypertension (PAH) market is projected to reach approximately $6,971 million in 2025 and grow at a CAGR of 6.3% between 2024 and 2034, driven by increasing disease prevalence and the launch of new pipeline products. Key companies like United Therapeutics, Gossamer Bio, Inhibikase Therapeutics, AllRock Bio Inc., Cereno Scientific, VASTHERA Co., Ltd., and Merck are advancing various therapies, with several clinical trial updates showing promising results for novel treatments. The report highlights significant market opportunities due to improved disease understanding, novel therapies, and government support for orphan drugs, with the US holding the largest proportion of diagnosed PAH cases.
Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 3.2% - Here's What Happened
Aerovate Therapeutics (NASDAQ:AVTE) saw its share price drop by 3.2% during mid-day trading, closing at $14.02 after reaching an intraday low of $13.80. The trading volume surged by 2,042% compared to its average daily volume, with approximately 266,446 shares changing hands. This decrease occurred despite recent institutional buying, including Goldman Sachs increasing its stake to 352,669 shares.
Aerovate Therapeutics (NASDAQ:AVTE) Shares Down 7.5% - Time to Sell?
Aerovate Therapeutics (NASDAQ:AVTE) saw its shares drop 7.5% during mid-day trading on Wednesday, with a significant surge in trading volume. Despite the selloff, several hedge funds, including Goldman Sachs, AQR, and Rhumbline Advisers, either increased their stakes or established new positions in the company. Aerovate is a clinical-stage biopharmaceutical firm focusing on inhaled therapies for pulmonary diseases.
George Eldridge
Abcuro Inc., a clinical-stage biotechnology company, has appointed George Eldridge as its new chief financial officer. Eldridge brings over 30 years of experience in finance and business operations within the biotechnology industry, including guiding Aerovate Therapeutics through its IPO. His expertise will be crucial as Abcuro prepares for key clinical data readouts for its lead asset, ulviprubart.
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics
Jade Biosciences, a portfolio company of RTW Biotech Opportunities (RTW), has merged with Nasdaq-listed Aerovate Therapeutics, with the combined entity retaining the Jade Biosciences name and JBIO ticker. This merger provides Jade Biosciences with a public listing and resources to advance its lead candidate, JADE-001, an investigational therapy for Immunoglobulin A nephropathy, into clinical trials in late 2025. RTW, which initially backed Jade in August 2024, views this merger as a validation of its strategy to support high-potential early-stage assets.
Jade Biosciences Completes Closing of Merger with Aerovate
Jade Biosciences announced the completion of its merger with Aerovate Therapeutics and an oversubscribed private investment round of approximately $300 million. The combined company, operating as Jade Biosciences, Inc., will trade on Nasdaq under "JBIO" and aims to advance best-in-class therapies for autoimmune diseases, with its lead candidate JADE-001 expected to enter the clinic in late 2025. This strategic move strengthens the company's financial foundation and pipeline development for novel treatments.
Jade Biosciences Completes Closing of Merger with Aerovate
Jade Biosciences announced the completion of its merger with Aerovate Therapeutics and an oversubscribed private placement of approximately $300 million. The combined company, operating as “Jade Biosciences, Inc.” and trading under "JBIO" on Nasdaq, aims to advance novel therapies for autoimmune diseases, with its lead candidate JADE-001 expected to enter clinical trials in late 2025. The merger also involved a reverse stock split for Aerovate common stock and a special cash dividend for pre-merger Aerovate stockholders.
Aerovate Therapeutics, Inc. SEC 10-Q Report
Aerovate Therapeutics released its Q1 2025 10-Q report, detailing a significant reduction in net loss to $2.5 million and a 92% workforce reduction following the discontinuation of its primary product, AV-101. The company has entered into a merger agreement with Jade Biosciences and is exploring strategic alternatives to maximize shareholder value. These strategic shifts include a special cash dividend declaration and plans for a reverse stock split, contingent on the merger's completion.
Aerovate Therapeutics and Jade Biosciences Merger Approved
Aerovate Therapeutics announced stockholder approval for its merger with Jade Biosciences, including a 1-for-35 reverse stock split. The combined company will trade on Nasdaq as "Jade Biosciences, Inc." (JBIO) starting April 29, 2025, with an estimated 32.2 million shares outstanding. A special cash dividend of $2.40 per share, totaling $69.6 million, will be paid to Aerovate stockholders of record as of April 25, 2025.
Aerovate approves reverse split ahead of Jade merger By Investing.com
Aerovate Therapeutics, Inc. announced a 1-for-35 reverse stock split ahead of its merger with Jade Biosciences, Inc., with the combined company set to trade as "JBIO" on Nasdaq from April 29, 2025. Stockholders will also receive a special cash dividend of an estimated $2.40 per share, totaling around $69.6 million. The merger combines Aerovate's focus on rare cardiopulmonary diseases with Jade Biosciences' development of autoimmune therapies, including its lead asset JADE-001.
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Aerovate Therapeutics expects to declare a cash dividend to pre-Merger stockholders of $67.6 – $69.6 million in connection with its proposed merger with Jade Biosciences. The dividend, subject to board and stockholder approval, is anticipated to be paid around the Closing, which is expected by April 30, 2025. Stockholders will vote on the merger on April 16, 2025.
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Aerovate Therapeutics announced an estimated cash dividend range of $67.6 – 69.6 million for pre-Merger stockholders, subject to board approval, in connection with its proposed merger with Jade Biosciences. The dividend will be paid upon the closing of the merger, which is contingent on Aerovate shareholder approval at a special meeting scheduled for April 16, 2025, with closing expected by April 30, 2025.
Aerovate Therapeutics Inc. (AVTE) reports earnings
Aerovate Therapeutics Inc. (AVTE) filed its 10-K report for the fiscal year ended December 31, 2024, detailing a halt in the development of AV-101 due to negative clinical trial results. The company is undergoing restructuring and exploring a merger with Jade Biosciences, Inc., following a net loss of $69.6 million. Future operations hinge on the successful completion of this proposed merger.
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Aerovate Therapeutics, Inc. (NasdaqGM: AVTE) and Jade Biosciences, where Aerovate shareholders will own approximately 1.6% of the combined company. Former Attorney General of Louisiana Charles C. Foti, Jr. and KSF are examining if the merger terms are fair to Aerovate shareholders and are offering legal consultation to affected shareholders.
